Home » Biohaven Achieves Orphan Drug Designation for ALS Drug Candidate
Biohaven Achieves Orphan Drug Designation for ALS Drug Candidate
The FDA has granted an orphan drug designation to Biohaven’s drug candidate BHV-0223, a developing treatment for amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease.
BHV-0223 is administered under the tongue as a dissolving tablet.
Biohaven plans to conduct a bioequivalence study for the candidate in 2017.
Upcoming Events
-
21Oct